New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinibREDWOOD CITY, Calif., ...

ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary ...

Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion (OPDP). | Sprout ...

The use of P-gp inducers is not recommended with ORLADEYO. ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and ...

The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura ...

Over 60% of U.S. adults take dietary supplements beyond vitamins and minerals. These include herbs, mushrooms, amino acids, ...

Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness ...

Gross proceeds from offering total $16.6 million.Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and ...

TELL YOUR DOCTOR ALL MEDICINES YOU TAKE. DON’T TAKE IF ALLERGIC OR WITH STRONG CYP3A4 INHIBITORS. GET HELP RIGHT AWAY FOR ALLERGIC REACTIONS LIKE TROUBLE BREATHING, FACE, MOUTH, TONGUE OR THROAT ...

Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, ...

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial ...